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Background: Following successful malaria control during the last decade, Ethiopia instituted a stepwise mal-
aria elimination strategy in selected low-transmission areas.
Methods: Cross-sectional surveys were conducted in Babile district, Oromia, Ethiopia from July to November 2017
to evaluate malaria infection status using microscopy and nested polymerase chain reaction (nPCR) and serological
markers of exposure targeting Plasmodium falciparum and Plasmodium vivax apical membrane antigen-1 (AMA-1).
Results: Parasite prevalence was 1.2% (14/1135) and 5.1% (58/1143) for P. falciparum and 0.4% (5/1135) and
3.6% (41/1143) for P. vivax by microscopy and nPCR, respectively. Antibody prevalence was associated with
current infection by nPCR for both P. falciparum (p<0.001) and P. vivax (p=0.014) and showed an age-
dependent increase (p<0.001, for both species). Seroconversion curves indicated a decline in malaria exposure
15 y prior to sampling for P. falciparum and 11.5 y prior to sampling for P. vivax, broadly following malaria inci-
dence data from district health ofﬁces, with higher antibody titres in adults than children for both species.
Conclusions: Malaria transmission declined substantially in the region with continuing heterogeneous but
measurable local transmission, arguing in favour of continued and tailored control efforts to accelerate the
progress towards elimination efforts.
Keywords: current infection, malaria elimination, metrics of transmission, serology
Introduction
Ethiopia achieved a remarkable reduction in malaria morbidity
and mortality following the major scale-up of control efforts in
2004/2005,1,2 in line with global trends during the same period.3
Following this success, Ethiopia instituted a stepwise approach
to eliminate malaria by 2030 in selected low-transmission areas
where control efforts were successful.4 With the aim of interrupting
local transmission, new tools and strategies were considered,
including endorsement of primaquine for transmission blocking in
Plasmodium falciparum and radical cure for Plasmodium vivax. As
transmission intensity declines, efforts to ﬁnd and treat the sparse
and heterogeneously distributed remaining infections results in
© The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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operational challenges,5 in part because a large fraction of these
infections is present at densities below the detection limit of stand-
ard diagnostics.6 In order to consolidate gains and progress to elim-
ination, improved tools for infection monitoring are needed.
Serological assays that detect human antibody responses to
malaria parasite antigens can be used to characterize current
and previous parasite exposure.7 Uniquely, serology allows retro-
spective examination of exposure history, including the effects
of interventions and the absence of recent exposure in elimin-
ation settings.8,9 In the present study, the current and past bur-
den of malaria in Babile, a district nominated for elimination by
the Federal Ministry of Health (FMoH) of Ethiopia, is examined by
microscopy, molecular assays and serology.
Materials and methods
Study area and population
A cross-sectional study was conducted from July to November 2017
in 14 villages that are located at an altitude range of 1280–1450 m
above sea level in Babile district within the East Hararghe zone of
the Oromia region of Ethiopia. Babile is one of the 239 districts nomi-
nated by the FMoH for malaria elimination efforts.4 The 14 villages
were selected using a computer-randomized list. Within these vil-
lages, convenience sampling was undertaken, with participants being
invited without any formal random selection. Study approval was
obtained from the Ethics Review Committees of the College of
Natural Sciences at Addis Ababa University (CNSDO/205/10/2017),
Armauer Hansen Research Institute (PO24/17) and Oromia Region
Health Bureau (BEFO/AHBIFH/1-8/2700). Informed written consent
was obtained from every participant or the parent/guardian of chil-
dren <18 y of age.
Sample collection and microscopy
Participants were asked about demographic characteristics,
intervention utilization, household characteristics and travel his-
tory. Finger prick blood samples were collected from participants
to prepare thin and thick blood ﬁlms and dried blood spots
(DBSs) on Whatman 3MM ﬁlter paper (Whatman, Maidstone,
UK). The DBS samples were air dried and stored individually in
sealed plastic bags with self-indicating silica gel beads (Loba
Chemie, Mumbai, India; CAS: 112926-00-8) and transported
under ambient conditions right after collection from the ﬁeld
site and stored at −20°C until further processing. Giemsa-
stained thick blood ﬁlms were considered negative if no para-
sites were observed after examining 200 ﬁelds.
Molecular parasite identiﬁcation and serological
assays
A combined approach for serum elution and DNA extraction
from 6-mm diameter DBS punches was used.10 Proper elution
of plasma from DBSs was assessed by the colour change of the
spots (to white) as well as the elution (to red/brown) after soak-
ing them 1–2 nights in saponin solution at ambient temperature
while on a horizontal shaker. If blood spots did not change
colour, still retaining the brownish blood colour, spots were
soaked further until a colour change was observed or excluded
from analyses as reported before.11 Plasmodium species were
identiﬁed using nested polymerase chain reaction (nPCR) target-
ing the small subunit 18S ribosomal RNA gene.12 Antibody
responses (immunoglobulin G) against apical membrane antigen-
1 of P. falciparum (AMA-1-3D7) and P. vivax (Sal-1) were tested
using enzyme-linked immunosorbent assay (ELISA)9,13 using
blood from malaria-naïve Europeans as negative controls and
World Health Organization (WHO) positive control sera (reference,
10/198 and 72/096; National Institute for Biological Standards
and Control).14,15 The WHO reference positive control sera were
included on every plate in six, with fourfold serial dilution starting
at the concentration of 1/100 in 0.05% phosphate-buffered
saline Tween-20 to translate optical density (OD) values to titres
as described before.16
Data analysis
Analyses were performed using the survey command in Stata 13
(StataCorp, College Station, TX, USA) to take into account the sam-
pling approach and in GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA, USA). The cut-off for seropositivity among samples
was determined as the mean OD of the negative control sera plus
3 standard deviations. Seroconversion curves were modelled using
a simple reversible catalytic model ﬁtted by maximum likelihood
for all study villages combined.11 The log-likelihood of a catalytic
conversion model that allowed for a change in transmission occur-
ring at iterative years was plotted to evaluate the time at which
seroconversion rates changed for each species.13 The time point at
which a change in transmission most likely had occurred was
determined using maximum log-likelihood. A likelihood ratio test
was used to determine if a model with a change in transmission
vs one without ﬁtted the data best (i.e., p<0.050). Reverse cumula-
tive distribution plots were used to evaluate differences in the geo-
metric mean antibody titres. Wilcoxon rank-sum test with
Bonferroni correction for multiple comparisons was used to test
between two continuous variables.
Results
Characteristics of study villages and the population
A total of 1144 samples, 46–128 per village, were analysed for
malaria infection using microscopy and nPCR as well as anti-
body responses to P. falciparum AMA-1 (Pf-AMA) and P. vivax
AMA-1 (Pv-AMA). The median age of participants was 12 y
(interquartile range [IQR] 7–26) and 52.1% (596/1144) of parti-
cipants were female. None of the participants had measured
fever at the moment of sampling. There was substantial vari-
ation in long-lasting insecticidal net ownership, ranging from
25.0% to 93.5% between villages (overall 69.0% [789/1144]
[95% conﬁdence interval {CI} 55.5–79.9]) (see Supplementary
Table 1 for detailed intervention utilization data). A substantial
reduction in the incidence and prevalence of malaria has been
recorded in the district since 2005, based on malaria control
program data from the FMoH and the district health ofﬁce
(Figure 1A, B). Data from the years prior to 2005 could not be
retrieved, as structured and organized data recording was only
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Figure 1. Annual parasite incidence, age seroprevalence plots and trends in antibody titres. Retrospective data from the district health bureau
between 2005 and 2016 is presented for (A) P. falciparum and (B) P. vivax. Indicated on the y-axis is annual parasite incidence per 1000 population
with the years indicated on the x-axis. Seroconversion curves are presented for (C) Pf-AMA (n=1144) and (D) Pv-AMA (n=1143) using a simple revers-
ible catalytic model ﬁtted by maximum likelihood. Triangles represent observed data and black lines represent predicted values. Dotted black lines
represent upper and lower 95% CIs for the predicted seroprevalence by age. A likelihood ratio test was used to determine if a model with a change
in transmission ﬁtted the data best. Associated p-values as well as seroconversion rate estimates pre- and post-change are shown on the plots.
Numbers indicate pre-change (λ1) and post-change (λ2) seroconversion values. Reverse cumulative distribution plots for age groups are indicated for
(E) Pf-AMA and (F) Pv-AMA for the four age groups (adults >15 y of age, black lines; children 10–15 y of age, black dotted lines; children 5–10 y of
age, grey lines; children <5 y of age, dotted grey lines). Shown in (E) and (F) are log10-transformed normalized OD values on the x-axis and the per-
centage of individuals having the indicated values or higher on the y-axis.
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begun in the study districts and across the country following the
intensiﬁed control measures.
Malaria infections detected by microscopy, nPCR and
seroprevalence
Microscopy detected 1.3% (95% CI 0.5 to 3.3) of P. falciparum
and 0.4% (95% CI 0.2 to 0.9) of P. vivax infections, whereas
nPCR detected 5.1% (95% CI 2.5 to 10.1) of P. falciparum and
3.6% (95% CI 2.2 to 5.7) of P. vivax infections. Antibodies
against Pf-AMA were detected in 11.2% (95% CI 6.5 to 18.6) of
study participants; for Pv-AMA this prevalence was 13.0% (95%
CI 5.3 to 28.6) (Table 1). Parasite prevalence estimates varied
between villages (Table 1) (p<0.001) for microscopy (range
0–6.2%), nPCR (range 1.1–24.5%) and antibody responses to Pf-
AMA (range 0–38.4%) and Pv-AMA (range 0–75.7%). Of the indi-
viduals who were seropositive for Pf-AMA, 17.2% (22/128) were
also positive for P. falciparum parasites by nPCR compared with
3.5% (36/1016) nPCR positivity among seronegatives (p<0.001).
Similarly, P. vivax parasite prevalence by nPCR was higher among
Pv-AMA seropositive (8.1% [11/149]) compared with seronega-
tive individuals (2.9% [29/994], p=0.014). Details on concord-
ance between tests are presented in Supplementary Table 2.
Despite this association at an individual level, there was no stat-
istically signiﬁcant association between village-level seropreva-
lence and nPCR parasite prevalence for P. falciparum (p=0.3559)
or P. vivax (p=0.1443).
Seroconversion rates and reverse cumulative
distribution
When samples from all villages were combined, the likelihood of
individuals testing seropositive increased with age for both Pf-
AMA (odds ratio [OR] 1.07 [95% CI 1.05 to 1.09], p<0.001) and
Pv-AMA (OR 1.02 [95% CI 1.01 to 1.04], p<0.001), which was
also apparent from the age-seroprevalence curves (Figure 1C,
D). Proﬁle likelihood analysis showed evidence for a change in
transmission occurring approximately 15.5 y (p<0.001) and
11.5 y (p=0.010) prior to the survey for Pf-AMA and Pv-AMA,
respectively. To examine age patterns in antibody responses in
more detail, reverse cumulative distribution (RCD) plots were
generated (Figure 1E, F). Higher antibody titres were detected in
adults than younger ages. The difference in antibody levels for
age groups (adults >15 y of age and children <15 y of age) was
signiﬁcant for both parasite species (p<0.001). When examining
antibody responses in more detail in children, differences were
observed between all age groups except between those <5 y of
age and those 5–10 y of age. Of the ﬁve children <5 y of age
who were Pf-AMA seropositive, P. falciparum infection was
detected by nPCR in three of them, thus demonstrating current
malaria exposure in this population. Among 14 children <5 y of
age who tested positive for Pv-AMA, infection was detected by
nPCR in only 4; the single 1-y-old child who was seropositive for
Pv-AMA antibodies also tested positive for P. vivax infection using
nPCR.
Discussion
Following the epidemics in the early 2000s, a substantial reduc-
tion in malaria incidence was reported in Ethiopia.17 In 2005,
Ethiopia introduced major scale-up efforts in malaria prevention
and control, including the introduction of artemisinin-based
combination therapy (ACT) as ﬁrst-line treatment,18 large-scale
distribution of long-lasting insecticidal nets, improved indoor
residual spraying campaigns and training of 30 000 health
extension workers in malaria diagnosis and treatment.19 This
effort was followed by a decline in new malaria cases by 66% in
2011 as compared with the pre-intervention period.1 In line
with this, the serological investigation in the present study
revealed a signiﬁcant decline in malaria transmission 15 y prior
to the study for P. falciparum and 11.5 y for P. vivax. Higher anti-
body titres were detected in adults compared with children, in
line with other studies and supporting the notion of antibody
acquisition following repeated exposure to malaria infections.
Serological responses to parasite antigens are informative tools
to reﬂect the history of malaria and monitor malaria control
programmes and have the potential to uncover heterogeneity in
the effectiveness of malaria control interventions.20,21
The change time predicted for P. falciparum infections in the
present study is earlier than the major scale-up of malaria inter-
ventions in the country. Of note, improved malaria control started
before 2002 with the replacement of chloroquine with sulpha-
doxine–pyrimethamine as the ﬁrst-line treatment for uncompli-
cated P. falciparum malaria around 1998 and improved access to
insecticide-treated nets around the same time.17 In line with this,
a nationwide decline in malaria incidence and death rates has
been recorded since 2001.17 A similar rate of decline in the years
prior to the massive scale-up was reported in a recent serological
study in the northwestern part of the country that even showed
an earlier predicted time point than the present study.22 The esti-
mate of time since changes in malaria burden in the current
study may thus be realistic. Moreover, rainfall and other climatic
patterns may affect transmission regardless of government-
imposed interventions.23,24 Variation in the change point esti-
mate from seroconversion curves also depends on sample size
and how sudden transmission changed.25
A strength of the current study is that it utilized both routine
tests (microscopy) and improved tools (PCR and serology) to con-
currently estimate current and historic levels of malaria transmis-
sion. Shortcomings include the limited number of examined
villages and villagers and the lack of formal random selection in
participant recruitment. The asymptomatic status of study parti-
cipants give us conﬁdence that no systematic bias was intro-
duced. An additional limitation is the reliance on AMA-1 as the
sole antigen. Although AMA-1 is a well-characterized marker of
historical exposure at the population level,26,27 malaria exposure
might have been missed by only measuring responses to a single
antigen. Further information could be generated by measuring
short-lived antibodies to indicate recent exposure to infection
across all ages.28
Despite these shortcomings, the current ﬁndings support evi-
dence for a decline in malaria burden. The current data further
demonstrate that malaria transmission is still ongoing in the
study area. While importation of malaria is possible, and an
M. Keffale et al.
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Table 1. Characteristics of study participants and malaria indicators per village
Village Age
(years),
median
(IQR)
Female,
% (n/N)
Previous
malaria,a %
(n/N)
Microscopy nPCR Serology
P. falciparum,
% (n/N)
P. vivax,
% (n/N)
Total, %
(n/N)
P. falciparum,
% (n/N)
P. vivax, %
(n/N)
Mixed
species,
% (n/N)
Total, % (n/N) Pf-AMA,
% (n/N)
Pv-AMA,
% (n/N)
1 9 (6–15) 57.7 (49/85) 3.6 (3/84) 0 (0/85) 0 (0/85) 0 (0/85) 7.1 (6/85) 4.7 (4/85) 0 (0/85) 11.8 (10/85) 3.5 (3/3/85) 4.7 (4/85)
2 12 (5–35) 54.7 (52/95) 7.4 (7/95) 5.3 (5/95) 0 (0/95) 5.3 (5/95) 19.1 (18/94) 3.2 (3/94) 2.1 (2/94) 24.5 (23/94) 22.1 (19/86) 3.5 (3/86)
3 30 (20–45) 17.8 (13/73) 26.0 (19/73) 0 (0/73) 1.4 (1/73) 1.4 (1/73) 5.5 (4/73) 4.1 (3/73) 1.4 (1/73) 11.0 (8/73) 38.4 (28/73) 4.1 (3/73)
4 12 (9–15) 45.3 (58/128) 16.4 (21/128) 2.3 (3/128) 0.8 (1/128) 3.1 (4/128) 3.1 (4/128) 0 (0/128) 0 (0/128) 3.1 (4/128) 3.1 (4/128) 1.6 (2/128)
5 7 (5–10) 52.0 (53/102) 31.4 (32/102) 0 (0/102) 0 (0/102) 0 (0/102) 1.0 (1/102) 1.0 (1/102) 1.0 (1/102) 3.0 (3/102) 2.0 (2/102) 2.0 (2/102)
6 11 (6–35) 52.2 (47/90) 37.8 (34/90) 4.9 (4/81) 1.2 (1/81) 6.2 (5/81) 9.0 (8/89) 6.7 (6/89) 1.1 (1/89) 16.9 (15/89) 14.4 (13/90) 15.6 (14/90)
7 17 (9–30) 72.9 (51/70) 18.6 (13/70) 1.4 (1/70) 1.4 (1/70) 2.8 (2/70) 8.6 (6/70) 5.7 (4/70) 0 (0/70) 14.3 (10/70 4.3 (3/70) 17.4 (12/69)
8 12 (7–27) 48.9 (39/80) 11.3 (9/80) 0 (0/80) 0 (0/80) 0 (0/80) 0 (0/80) 1.3 (1/80) 1.3 (1/80) 2.6 (2/80) 6.3 (5/80) 38.8 (31/80)
9 15 (7–25) 41.4 (29/70) 40.4 (23/57) 0 (0/70) 0 (0/70) 0 (0/70) 1.4 (1/70) 1.4 (1/70) 0 (0/70) 2.8 (2/70) 8.6 (6/70) 75.7 (53/70)
10 16 (9–35) 60.2 (56/93) 44.1 (41/93) 1.1 (1/93) 1.1 (1/93) 2.2 (2/93) 2.2 (2/93) 6.5 (6/93) 1.1 (1/93) 9.7 (9/93) 18.3 (17/93) 23.7 (22/93)
11 10 (6–15) 56.1 (37/66) 40.9 (27/66) 0 (0/66) 0 (0/66) 0 (0/66) 0 (0/66) 3.0 (2/66) 0 (0/66) 3.0 (2/66) 13.6 (9/66) 0 (0/66)
12 16 (10–30) 45.5 (40/88) 39.8 (35/88) 0 (0/88) 0 (0/88) 0 (0/88) 0 (0/88) 1.1 (1/88) 0 (0/88) 1.1 (1/88) 14.8 (13/88) 0 (0/46)
13 4.5 (3–9) 71.7 (33/46) 21.7 (10/46) 0 (0/46) 0 (0/46) 0 (0/46) 0 (0/46) 4.4 (2/46) 0 (0/46) 4.4 (2/46) 0 (0/46) 0 (0/46)
14 10 (4–30) 67.2 (39/58) 24.1 (14/58) 0 (0/58) 0 (0/58) 0 (0/58) 1.7 (1/58) 0 (0/58) 0 (0/58) 1.7 (1/58) 5.2 (3/58) 1.7 (1/58)
Total 12 (7–30) 52.1 (596/1144) 25.5 (288/1130) 1.2 (14/1135) 0.4 (5/1135) 1.7 (19/1135) 4.5 (51/1143) 3.0 (34/1143) 0.6 (7/1143) 8.0 (92/1142) 11.0 (125/1135) 13.0 (147/1134)
aPrevious malaria refers to self-reported history of malaria in the last year that was captured with a questionnaire.
Transactions
of
the
RoyalSociety
of
TropicalM
edicine
and
H
ygiene
309
D
ow
nloaded from
 https://academ
ic.oup.com
/trstm
h/article-abstract/113/6/305/5423650 by London School of H
ygiene & Tropical M
edicine user on 14 June 2019
important source of infection in several low-endemic settings,
our ﬁndings of detectable serological responses in children, often
accompanied by PCR-detected infection, suggest that there is still
non-negligible local transmission. Continued efforts are required
to further reduce malaria in the region. Novel tools that can inter-
rupt transmission and improved strategies on enhanced commu-
nity case management to ﬁnd the few remaining infections that
plausibly maintain the infectious parasite reservoir are of para-
mount importance in accelerating progress towards elimination.
The striking variation in malaria indicators between villages high-
lights the need for a better understanding of (variation in) the
uptake of interventions and potentially tailor interventions to
local needs to accelerate elimination efforts in the region.
Supplementary data
Supplementary data are available at Transactions online (http://
trstmh.oxfordjournals.org/).
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